ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jan 11, 2012
Lululemon Raises Guidance; Our Valuation Remains Unchanged
With room for growth both in North America and abroad, we think Lululemon remains a growth company that could yield high returns for those with high risk tolerance. However, with shares trading up from $42 to $60 in less than a month, we'd wait for a larger margin of safety before getting too excited about the name.
Jan 10, 2012
Life Technologies Unveils One-Day Genome Sequencer Product; Shares Jump 8% to Our $47 Fair Value Estimate
Life Technologies announced that it has begun accepting orders for a product named the Ion Proton Sequencer that could sequence a person's entire genome in just one day (more expensive, competing machines can take weeks or longer to do the same procedure). We had been expecting valuation upside from the firm, and its shares have now converged to our $47 fair value estimate.
Jan 10, 2012
WebMD Cuts Through Our Fair Value Estimate; Falls Almost 30% Today
WebMD surprised investors this morning. The company said it is no longer 'for sale', disclosed that its CEO had resigned, and warned that 2012 profits would disappoint. Our discounted cash-flow process had identified a buy-out premium in the shares, and we had been expecting a significant move lower into the high $20s based on our fair value estimate. We think WebMD's shares are fairly valued after the move.
Jan 10, 2012
Alcoa Posts Weak Fourth-Quarter Results, Will Focus on Preserving Cash Balance in 2012
Alcoa posted weak fourth-quarter results, though its outlook for the aerospace and automotive end markets remain strong. The aluminum giant will manage operations to maximize cash flow during 2012 amid ongoing weakness in aluminum pricing.
Jan 9, 2012
Despite Market Uncertainty, Our Best Ideas Portfolio Continues to Widen Outperformance
The portfolio in our Best Ideas Newsletter is now outpacing the S&P 500 (SPY) by over 20 percentage points through January 7, 2012. View an interim-issue snapshop of our performance.
Jan 9, 2012
Stick to the Smoothies, Not the Stock with Jamba
We don't find Jamba that compelling and encourage investors to steer clear of this penny stock. We think it is priced appropriately on the basis of option value, considering its debt-free balance sheet and still-improving same-store-sales trends.
Jan 6, 2012
Macy's Hits Multi-Year High; Continues to Converge to Our $42 Fair Value Estimate
We initiated coverage of Macy's in early October with a fair value estimate of $42 per share and a VBI rating of 9. The stock has since rallied nearly 30% to the mid-$30s to hit a multi-year high, and we think further valuation upside remains in the name.
Jan 6, 2012
Alcoa Cuts Smelter Capacity on Reduced Aluminum Prices
Alcoa plans to scale back smelter capacity by 12% in the wake of weak aluminum prices, which have fallen by almost 30% since the peak last year. We remain on the sidelines with respect to Alcoa's shares and point to Precision Castparts as a better metals play.
Jan 4, 2012
A Name for Your Radar: Collector's Universe (CLCT)
We dig into the investment case of Collector's Universe. Though its yield is attractive at almost 9%, we'd only grow constructive on the shares if they fell into the single digits.
Jan 2, 2012
Valuentum's January Edition of its Dividend Growth Newsletter!
The January edition of our Dividend Growth Newsletter is now available.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.